p38 MAPK inhibition in nucleus pulposus cells: A potential target for treating intervertebral disc degeneration

Spine

Volumn 32, Issue 25, 2007, Pages 2827-2833

  Studer, Rebecca K ^a,b   Aboka, Alex M ^b   Gilbertson, Lars G ^d   Georgescu, Helga ^b   Sowa, Gwendolyn ^b,c   Vo, Nam ^b   Kang, James D ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Ferguson Laboratory for Orthopaedic Research   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Disc degeneratio; IL 1; Nucleus pulposus cells; p38 MAPK; Signal transduction; TNF

Indexed keywords

ALGINIC ACID; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PROSTAGLANDIN E2; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4-(4-FLUOROPHENYL)-2-(4-HYDROXYPHENYL)-5-(4-PYRIDYL)IMIDAZOLE; GLUCURONIC ACID; HEXURONIC ACID; IMIDAZOLE DERIVATIVE; INTERLEUKIN 1BETA; MMP3 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CULTURE MEDIUM; ELECTIVE SURGERY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; INTERVERTEBRAL DISK DEGENERATION; MALE; NUCLEUS PULPOSUS; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; CELL CULTURE; CULTURE TECHNIQUE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; INTERVERTEBRAL DISK; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; SPINE DISEASE; TIME;

ADULT; ALGINATES; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DINOPROSTONE; FEMALE; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; IMIDAZOLES; INTERLEUKIN-1BETA; INTERVERTEBRAL DISK; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; NITRIC OXIDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; SIGNAL TRANSDUCTION; SPINAL DISEASES; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 39049119345     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e31815b757a     Document Type: Article

References (43)

1. Luo X, Pietrobon R, Sun SX, et al. Estimates and patterns of direct health care expenditures among individuals with back pain in the United States. Spine 2004;29:79-86.
2. Borenstein D. Epidemiology, etiology, diagnostic evaluation, and treatment of low back pain. Curr Opin Rheumatol 1992;4:226-32.
3. Shimer AL, Chadderdon RC, Gilbertson LG, et al. Gene therapy approaches for intervertebral disc degeneration. Spine 2004;23:2770-8.
4. Walsh AJL, Bradford DS, Lotz JC. In vivo growth factor treatment of degenerated intervertebral discs. Spine 2004;29:156-63.
5. Masuda K, An HS. Prevention of disc degeneration with growth factors. Eur Spine J 2006;15(suppl):422-32.
6. Thompson JP, Oegema TR, Bradford DS. Stimulation of mature canine intervertebral disc by growth factors. Spine 1991;16:253-60.
7. Kim D-J, Moon S-H, Kim H, et al. Bone morphogenetic protein-2 facilitates expression of chondrogenic, not osteogenic, phenotype of human intervertebral disc cells. Spine 2003;28:2679-84.
8. Moon SH, Gilbertson LG, Nishida K, et al. Human intervertebral disc cells are genetically modifiable by adenovirus-mediated gene transfer: implications for the clinical management of intervertebral disc disorders. Spine 2000;25:2573-9.
9. Zhang Y, An HS, Thonar EJ-MA, et al. Comparative effects of bone morphogenetic proteins and sox0 overexpression on extracellular matrix metabolism of bovine nucleus pulposus cells. Spine 2006;31:2173-9.
10. Kang JD, Georgescu HI, McIntyre-Larkin L, et al. Herniated lumbar intervertebral discs spontaneously produce matrix metalloproteinases, nitric oxide, interleukin-6, and prostaglandin E2. Spine 1996;21:271-7.
11. Handa T, Ishihara H, Ohshima H, et al. Effects of hydrostatic pressure on matrix synthesis and matrix metalloproteinase production in the human lumbar intervertebral disc. Spine 1997;22:1085-91.
12. Kanemoto M, Hukuda S, Komiya Y, et al. Immunohistochemical study of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 human intervertebral discs. Spine 1996;21:1-8.
13. Sobajima S, Shimer AL, Chadderdon RC, et al. Quantitative analysis of gene expression in a rabbit model of intervertebral disc degeneration by real-time polymerase chain reaction. Spine J 2005;5:14-23.
14. Kang JD, Stefanovic-Racic M, McIntyre LA, et al. Toward a biochemical understanding of human intervertebral disc degeneration and herniation. Spine 1997;22:1065-73.
15. Roberts S, Butler RC. Inflammatory mediators as potential therapeutic targets in the spine. Curr Drug Targets Inflamm Allergy 2005;4:257-66.
16. Wang Y-J, Shi Q, Lu WW, et al. Cervical intervertebral disc degeneration induced by unbalanced dynamic and static forces: a novel in vivo rat model. Spine 2006;31:1532-8.
17. LeMaitre CH, Freemont AJ, Hoyland JA. The role of Interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Arthritis Res Ther 2005;7:R732-45.
18. Weiler C, Nerlich AG, Bachmeier BE, et al. Expression and distribution of tumor necrosis factor alpha in human lumbar intervertebral discs: a study in surgical specimen and autopsy controls. Spine 2004;30:44-54.
19. Jimbo K, Park JS, Yokosuka K, et al. Positive feedback loop of Interleukin-1beta upregulating production of inflammatory mediators in human intervertebral disc cells in vitro. J Neurosurg Spine 2005;2:589-95.
20. Amin AR, Dave M, Attur M, et al. COX-2, NO, and cartilage damage and repair. Curr Rheumatol Rep 2000;2:447-53.
21. van der Kraan PM, van den Berg WB. Anabolic and destructive mediators in osteoarthritis. Curr Opin Clin Nutr Metab Care 2000;3:205-11.
22. Rannou F, Lee T-S, Zhou R-H, et al. Intervertebral disc degeneration: the role of the mitochondrial pathway in annulus fibrosus cell apoptosis induced by overload. Am J Pathol 2004;164:915-24.
23. Studer RK, Bergman R, Stubbs T, et al. Chondrocyte response to growth factors is modulated by p38 MAPK inhibition. Arthritis Res Ther 2003;6:R56-64.
24. Studer RK, Chu CR. P38 MAPK and COX2 inhibition modulate human chondrocyte response to TGF-beta. J Orthop Res 2005;23:454-61.
25. Thompson JP, Pearce RH, Schechter MT, et al. Preliminary evaluation of a scheme for grading the gross morphology of the human intervertebral disc. Spine 1990;15:411-5.
26. Wallach CJ, Sobajima S, Watanabe Y, et al. Gene transfer of the catabolic inhibitor TIMP-1 increases measured proteoglycans in cells from degenerated human intervertebral discs. Spine 2003;28:2331-7.
27. Lali FV, Hunt AD, Turner SJ, et al. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in IL-2 stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem 2000;275:7395-402.
28. Seguin CA, Bojarski M, Pilliar RM, et al. Differential regulation of matrix degrading enzymes in a TNFα-induced model of nucleus pulposus tissue degeneration. Matrix Biol 2006;25:409-18.
29. Seguin CA, Pilliar RM, Roughley PJ, et al. Tumor necrosis factorα modulates matrix production and catabolism in nucleus pulposus tissue. Spine 2005;30:1940-8.
30. Masuko-Hongo K, Berenbaum F, Humbert L, et al. Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage. Arthritis Rheum 2004;50:2829-38.
31. Miyamoto H, Saura R, Coita M, et al. The role of cyclooxygenase-2 in lumbar disc herniation. Spine 2002;27:2477-83.
32. Miyamoto H, Doita M, Nishida K, et al. Effects of cyclic mechanical stress on the production of inflammatory agents by nucleus pulposus and anulus fibrosus derived cells in vitro. Spine 2006;31:4-9.
33. Goldring MB, Berenbaum R. The regulation of chondrocyte function by proinflammatory mediators. Clin Orthop 2004;427(suppl):37- 46.
34. Ridley SH, Dean JL, Sarsfield SJ, et al. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Lett. 1998;439:75-80.
35. Bradbury DA, Corbett L, Knox AJ. PI 3-kinase and MAP kinase regulate bradykinin induced prostaglandin E2 release in human pulmonary artery by modulating COX-2 activity. FEBS Lett 2004;560:30-4.
36. Kang JD, Georgescu HI, McIntyre-Larkin L, et al. Herniated lumbar intervertebral discs spontaneously produce matrix metalloproteinases, nitric oxide, IL-6, and PGE-2. Spine 1996;21:272-7.
37. Burke JG, Watson RW, McCormack D, et al. Intervertebral discs which cause low back pain secrete high levels of proinflammatory mediators. J Bone Joint Surg Br 2002;84:196-201.
38. Li H, Zou X, Baatrup A, et al. Cytokine profiles in conditioned media from cultured human intervertebral disc tissue. Acta Orthop 2005;76:115-21.
39. Wong PKK, Campbell IK, Egan PJ, et al. The role of the IL-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum 2003;48:1177-89.
40. Legendre F, Dudhia J, Pujol J-P, et al. JAK/STAT but not ERK1/ERK2 pathway mediated IL-6/soluble IL-6R down-regulation of type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. J Biol Chem 2003;278:2903-12.
41. Legendre F, Bogdanowicz P, Boumediene K, et al. Role of IL-6/IL-6R-induced signal tranducers and activators of transcription and MAPK/ERK in upregulation of matrix metalloproteinase and ADAMTS gene expression in articular chondrocytes. J Rheumatol 2005;32:1307-16.
42. Flannery CR, Little CB, Hughes CE, et al. IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. Matrix Biol 2000;19:549-53.
43. Lee GM, Tioran ME, Jansen M, et al. Development of selective tolerance to IL-1beta by human chondrocytes in vitro. J Cell Physiol 2002;192:113-24.